Skip Ribbon Commands
Skip to main content
Sign In

26556 NASH FibroSure® Plus (550960)

NASH FibroSure® Plus (550960)
Test Code: NASHFSO
Synonyms/Keywords

​​​​Fatty Liver Disease, NAFLD, Nonalcoholic Fatty Liver Disease, Noninvasive Liver Biopsy, Steatohepatitis

Test Components

a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, y-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, and fasting glucose​

Useful For

​This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Quantitative results of 10 biochemicals in combination with age and gender are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.41) precludes the diagnosis of NASH.

Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/Tube
Specimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Minimum of 8 hours​
Serum​

Serum Separator Tube (SST)


Red Top Tube (RTT)
3.5 mL
 2 mL
Collection Processing Instructions

Patient Preparation:  Patient should be fasting for at least eight hours.

The patient's age and gender must be submitted, but the patient's height and weight are NOT required for NASH FibroSure® Plus testing.

Separate serum from cells within two hours of collection.​

Specimen Stability Information
Specimen Type
TemperatureTime
​​


Serum



​Ambient
​72 hours
​Refrigerated at 2°C to 8°C 
​72 hours
Frozeat -70°C (preferred)
​7 days
​Freeze/thaw cycles
​Stable x1
Rejection Criteria
​Gross hemolysis
​Gross lipemia 
​Improper labeling
Nonfasting specimen
Patient younger than 14 years of age​

Interference

​NASH FibroSure® Plus is recommended for patients with suspected nonalcoholic fatty liver disease. It is not recommended for patients with other liver diseases. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra- hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
LabCorp of America​
Testing schedule may vary. 
​4 to 6 days​
Quantitative results of 10 biochemicals in combination with age and gender are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.41) precludes the diagnosis of NASH.
Reference Lab
Test Information

​This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Quantitative results of 10 biochemicals in combination with age and gender are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.41) precludes the diagnosis of NASH.

Reference Range Information
Performing Location
Reference Range
LabCorp of America​
Interpretive report​
Outreach CPTs
CPTModifier
(if needed)
Quantity
DescriptionComments

83883
1​Nephelometry
​83010

1​Haptoglobin
​82172

1​Apolipoprotein
​82247

1​Bilirubin Total
​84460

1​​ALT
​82465

1​​Cholesterol
​84478

1​​Triglyceride
​82947

1​Glucose
​84450

1​AST​
​​82977
1​GGT
Synonyms/Keywords

​​​​Fatty Liver Disease, NAFLD, Nonalcoholic Fatty Liver Disease, Noninvasive Liver Biopsy, Steatohepatitis

Test Components

a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, y-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, and fasting glucose​

Ordering Applications
Ordering Application
Description
​​Cerner
​NASH FibroSure Plus (550960)

If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/Tube
Specimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
Minimum of 8 hours​
Serum​

Serum Separator Tube (SST)


Red Top Tube (RTT)
3.5 mL
 2 mL
Collection Processing

Patient Preparation:  Patient should be fasting for at least eight hours.

The patient's age and gender must be submitted, but the patient's height and weight are NOT required for NASH FibroSure® Plus testing.

Separate serum from cells within two hours of collection.​

Specimen Stability Information
Specimen Type
TemperatureTime
​​


Serum



​Ambient
​72 hours
​Refrigerated at 2°C to 8°C 
​72 hours
Frozeat -70°C (preferred)
​7 days
​Freeze/thaw cycles
​Stable x1
Rejection Criteria
​Gross hemolysis
​Gross lipemia 
​Improper labeling
Nonfasting specimen
Patient younger than 14 years of age​

Interference

​NASH FibroSure® Plus is recommended for patients with suspected nonalcoholic fatty liver disease. It is not recommended for patients with other liver diseases. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra- hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

Useful For

​This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Quantitative results of 10 biochemicals in combination with age and gender are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.41) precludes the diagnosis of NASH.

Test Components

a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, y-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, and fasting glucose​

Reference Range Information
Performing Location
Reference Range
LabCorp of America​
Interpretive report​
For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
LabCorp of America​
Testing schedule may vary. 
​4 to 6 days​
Quantitative results of 10 biochemicals in combination with age and gender are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.41) precludes the diagnosis of NASH.
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPTModifier
(if needed)
Quantity
DescriptionComments

83883
1​Nephelometry
​83010

1​Haptoglobin
​82172

1​Apolipoprotein
​82247

1​Bilirubin Total
​84460

1​​ALT
​82465

1​​Cholesterol
​84478

1​​Triglyceride
​82947

1​Glucose
​84450

1​AST​
​​82977
1​GGT
For most current information refer to the Marshfield Laboratory online reference manual.